Evidence map›Paper›PMID 34084755›Full record

ReviewFrontiers in cellular and infection microbiology2021

RNA Regulated Toxin-Antitoxin Systems in Pathogenic Bacteria.

David D Sarpong, Erin R Murphy

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in cellular and infection microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 14 citations in OpenAlex.

  1. Genomic profiling ofMicrobiology spectrum · 2026
    Article
  2. Genomic characterization of a pathogenicFrontiers in microbiology · 2026
    Article
  3. Review
  4. Type II Toxin-Antitoxin Systems inInfection and drug resistance · 2025
    Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Battle for Metals: Regulatory RNAs at the Front Line.Frontiers in cellular and infection microbiology · 2022
    Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

David D SarpongDepartment of Biological Sciences, Ohio University, Athens, OH, United States.
Erin R MurphyInfectious and Tropical Diseases Institute, Ohio University, Athens, OH, United States.
Ohio University · US

Funding

Form and Function of Tandem Duplicate Small RNA Molecules in Shigella dysenteriaeR15AI103887 · NIAID · OHIO UNIVERSITY ATHENS · PI MURPHY, ERIN R · 2013 to 2013
$446k
NIAID NIH HHS R15 AI103887
6 · The paper itself

Abstract

The dynamic host environment presents a significant hurdle that pathogenic bacteria must overcome to survive and cause diseases. Consequently, these organisms have evolved molecular mechanisms to facilitate adaptation to environmental changes within the infected host. Small RNAs (sRNAs) have been implicated as critical regulators of numerous pathways and systems in pathogenic bacteria, including that of bacterial Toxin-Antitoxin (TA) systems. TA systems are typically composed of two factors, a stable toxin, and a labile antitoxin which functions to protect against the potentially deleterious activity of the associated toxin. Of the six classes of bacterial TA systems characterized to date, the toxin component is always a protein. Type I and Type III TA systems are unique in that the antitoxin in these systems is an RNA molecule, whereas the antitoxin in all other TA systems is a protein. Though hotly debated, the involvement of TA systems in bacterial physiology is recognized by several studies, with the Type II TA system being the most extensively studied to date. This review focuses on RNA-regulated TA systems, highlighting the role of Type I and Type III TA systems in several pathogenic bacteria.

Indexed as

AntitoxinsBacterial ToxinsToxin-Antitoxin SystemsBacteriaBacterial ProteinsRNAAntitoxinsBacterial ProteinsBacterial ToxinsRNAbacteriapathogenRNAsRNAtoxin-antitoxin (TA)

Identifiers

PMID34084755
PMCPMC8167048
OpenAlexW3161608049

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.